Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$374.46 USD

374.46
2,792,694

+7.92 (2.16%)

Updated Aug 11, 2025 04:00 PM ET

After-Market: $374.40 -0.06 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks News

The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.

Mark Vickery headshot

Delta Variant Catches Up with the Stock Market

Today, worries about growth and demand, at least partially caused by the Delta variant of Covid-19 manifesting in pockets of America.

Zacks Equity Research

Travere (TVTX) Announces Data on Rare Kidney Disease Drug

Travere (TVTX) announces positive interim data from the ongoing study of its investigational candidate, sparsentan, for the treatment of IgAN, a rare kidney disorder. Resultantly, the stock rises

Zacks Equity Research

Moderna (MRNA) Begins Rare Disease Study, Inks Supply Agreement

Moderna (MRNA) doses first patient in phase I/II study with mRNA-3705 for the treatment of a rare multi-organ disorder. The company also revises the supply agreement with the Canadian Government for its COVID vaccine.

Zacks Equity Research

Sesen's (SESN) Bladder Cancer Drug Vicineum Gets CRL From FDA

Sesen's (SESN) biologics license application filed for Vicineum to treat BCG-unresponsive non-muscle invasive bladder cancer fails to secure approval. The stock declines resultantly.

Zacks Equity Research

Pfizer (PFE) Gets Fast Track Tag for Wilson Disease Candidate

The FDA bestows a Fast Track designation to Pfizer (PFE) and partner Vivet Therapeutics' clinical-stage gene therapy, VTX-801, for the treatment of Wilson disease.

Zacks Equity Research

Organon's (OGN) Q2 Earnings & Revenues Surpass Estimates

Organon's (OGN) earnings and revenues beat estimates in the second quarter of 2021. Stock up in pre-market trading.

Zacks Equity Research

Perrigo (PRGO) Q2 Earnings Lag, Sales Hurt by Weak Cold Season

Perrigo (PRGO) reports dismal second-quarter 2021 results. Stock down.

Zacks Equity Research

ChemoCentryx (CCXI) Q2 Loss Wider Than Expected, Sales Down

ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the second quarter and misses on sales.

Zacks Equity Research

Axsome (AXSM) Q2 Earnings Top, AXS-05 Approval Likely Delayed

Axsome Therapeutics (AXSM) reports narrower-than-expected Q2 loss. Yet, share price falls steeply after it notified of a potential delay in the approval of AXS-05 for major depressive disorder

    Zacks Equity Research

    QIAGEN (QGEN) Gains FDA's EUA for SARS CoV-2 Antigen Test

    QIAGEN's (QGEN) QIAreach SARS CoV-2 Antigen Test can detect SARS CoV-2 antigens in 2-15 minutes and can process an average of 30 swab samples per hour.

    Zacks Equity Research

    Viatris (VTRS) Beats on Q2 Earnings & Sales, Raises View

    Viatris (VTRS) beats on Q2 earnings and sales. The company raises annual guidance.

    Zacks Equity Research

    Bayer's (BAYRY) Q2 Earnings & Revenues Surpass Estimates

    Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2021.

    Zacks Equity Research

    Amicus (FOLD) Q2 Earnings & Revenues Top Estimates, Stock Up

    Amicus (FOLD) reports narrower-than-expected Q2 loss. The sales figure also beat estimates. Following encouraging results and positive progress with pipeline candidates, the stock rises.

    Zacks Equity Research

    Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics

    Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.

    Zacks Equity Research

    How to Find Strong Buy Medical Stocks Using the Zacks Rank

    The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

    Zacks Equity Research

    Vertex Pharma and Twilio highlighted as Zacks Bull and Bear of the Day

    Vertex Pharma and Twilio highlighted as Zacks Bull and Bear of the Day

    Kevin Cook headshot

    Bull of the Day: Vertex Pharmaceuticals (VRTX)

    Scientific innovation in the treatment of cystic fibrosis bolsters success and pipeline confidence

    Zacks Equity Research

    Horizon's (HZNP) Q2 Earnings and Revenues Beat, Stock Up

    Horizon (HZNP) beats on both earnings and revenues in Q2. Sales soared on account of the relaunch of the thyroid eye disease drug Tepezza. As a result, stock rises.

    Zacks Equity Research

    Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down

    Clovis (CLVS) reports wider-than-expected loss for second-quarter 2021. Sales of the company's sole marketed drug, Rubraca, decreased year over year due to COVID-19 impacts.

    Zacks Equity Research

    Moderna (MRNA) Q2 Earnings Top, COVID-19 Vaccine Brings $4.2B

    Moderna's (MRNA) COVID-19 vaccine continues to enjoy robust demand. The company delivered 199 million doses of its COVID-19 vaccine during the second quarter.

    Zacks Equity Research

    Here is Why Growth Investors Should Buy Vertex (VRTX) Now

    Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.

    Zacks Equity Research

    Deciphera (DCPH) Q2 Loss Wider Than Expected, Revenues Beat

    Deciphera (DCPH) posts wider-than-expected loss in the second quarter due to rising R&D costs. Sales beat estimates on the encouraging uptake of Qinlock.

    Zacks Equity Research

    Zacks.com featured highlights include: Walmart, Vertex Pharma, Medical Properties Trust, TriNet Group and TriMas Corp

    Zacks.com featured highlights include: Walmart, Vertex Pharma, Medical Properties Trust, TriNet Group and TriMas Corp

    Zacks Equity Research

    Ultragenyx (RARE) Q2 Loss Widens Y/Y, Revenues Beat Estimates

    Ultragenyx Pharmaceutical's (RARE) Q2 sales increase year over year while loss widens.

    Sanghamitra Saha headshot

    Rising P/E: A Trick to Land on 5 Winning Stocks

    Want to try a different approach? Tap five stocks with increasing P/E ratios.